NCT03098589 2025-03-30Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)CelgeneCompleted1,149 enrolled
NCT02921802 2022-06-14A Study of Special Use Results Surveillance of Revlimid 5mg CapsulesCelgeneCompleted4,626 enrolled
NCT02922543 2022-06-14A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of UseCelgeneCompleted361 enrolled
NCT00264095 2014-04-28An Observational Study of Blood Management Techniques in Oncology Surgical TreatmentJanssen-Cilag B.V.Completed488 enrolled